Delivery Order SPE2DB22D3401-SPE2DB25FT2JJ

Award Date 3/3/25
Potential Completion Date 3/4/25
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,336.96 fixed-price delivery order is for the medication EMGALITY 120 MG/ML PENML, with a completion date of November 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,011.52 Firm Fixed Price Delivery Order contract is for the supply of EMGALITY 120 MG/ML PENML, a prescription medication. The contract has an ultimate completion date of September 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,844.16 firm fixed-price delivery order, contract number SPE2DB22D2007|SPE2DB25FH9GN, is for the supply of EMGALITY 120 MG/ML PENML, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,074.80 firm fixed-price Delivery Order (SPE2DX15D1053|SPE2DX25F6JVS) is for the supply of EMGALITY 120 MG/ML PENML, a pharmaceutical product. The contract has a period of performance through March 5, 2025 and does not have any set-aside designation, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,729.00 firm fixed-price delivery order is for the supply of EMGALITY 120 MG/ML PENML, a medication. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, valued at $2,425.44, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order to supply EMGALITY 120 MG/ML PENML medication, with a completion date of February 3, 2025. The contract is a firm fixed-price arrangement, without any set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,131.14 Firm Fixed Price Delivery Order contract is for the provision of EMGALITY 120 MG/ML PENML, a pharmaceutical product. The contract has an ultimate completion date of January 13, 2025 and was awarded on January 10, 2025. The award is not designated as a set-aside contract. Amerisourcebergen holds a...
The federal contract award SPE2DX15D6028|SPE2DX24FWPVJ, valued at $1,588.54, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of the pharmaceutical product EMGALITY 120MG/ML 1S and does not have a set-aside designation. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award, identified as SPE2DB24D1007|SPE2DB25FBZZN, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,058.40, is for the delivery of Emgality 120 mg/ml Penml, a medication. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of EMGALITY 120 MG/ML PENML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $2,718.00, is a delivery order issued under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 through December 31, 2025. This...
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT2JJ
    Delivery Order

This federal contract award, valued at $2,238.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EMGALITY 120 MG/ML PENML, a pharmaceutical product, and does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 6/2/25, 9:51 AM